Arcus Biosciences Quarterly Cash Flow Statement
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcus Biosciences free cash flow
In the quarter ended Jun 30, 2026, Arcus Biosciences generated -$119.0 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$119.0 million, a free-cash-flow margin of -290.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Arcus Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -91.00M | -128.00M | -106.00M | -135.00M | 0 | -112.00M | -94.00M | -92.00M | -93.00M | -4.00M | -81.00M | -71.00M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.00M | 2.00M | 3.00M | 2.00M | 2.00M | 3.00M | 3.00M | 2.00M | 2.00M | 3.00M | 3.00M | 1.00M |
| Stock-Based Compensation | 15.00M | 19.00M | 15.00M | 14.00M | 15.00M | 16.00M | 17.00M | 19.00M | 20.00M | 20.00M | 18.00M | 18.00M |
| Change in Working Capital | -42.00M | -20.00M | -26.00M | -13.00M | -152.00M | -25.00M | -37.00M | 66.00M | -39.00M | -43.00M | -15.00M | -26.00M |
| Operating Cash Flow | -119.00M | -138.00M | -120.00M | -97.00M | -133.00M | -132.00M | -100.00M | 26.00M | -94.00M | -2.00M | -88.00M | -63.00M |
| Capital Expenditures | 0 | 0 | -1.00M | 0 | 0 | -1.00M | -1.00M | -1.00M | 0 | -4.00M | -6.00M | -10.00M |
| Investing Cash Flow | 52.00M | 114.00M | -182.00M | 79.00M | 137.00M | 32.00M | 51.00M | -29.00M | 63.00M | -169.00M | 28.00M | 11.00M |
| Debt Issued | — | — | 0 | 0 | — | — | 0 | 47.00M | — | — | 0 | — |
| Financing Cash Flow | 16.00M | 3.00M | 286.00M | 8.00M | 52.00M | 142.00M | -2.00M | 48.00M | 2.00M | 229.00M | 3.00M | 6.00M |
| Net Change in Cash | -51.00M | -21.00M | -16.00M | -10.00M | 56.00M | 42.00M | -51.00M | 45.00M | -29.00M | 58.00M | -57.00M | -46.00M |
| Free Cash Flow | -119.00M | -138.00M | -121.00M | -97.00M | -133.00M | -133.00M | -101.00M | 25.00M | -94.00M | -6.00M | -94.00M | -73.00M |
This table shows 12 quarterly periods of Arcus Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RCUS's reporting calendar. What is a cash flow statement?